Get the Stockscreener App
4.72
3.74%
0.17
After Hours:
4.73
0.01
+0.21%
Omniab Inc stock is traded at $4.72, with a volume of 673.86K.
It is up +3.74% in the last 24 hours and up +8.51% over the past month.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
See More
Previous Close:
$4.55
Open:
$4.6
24h Volume:
673.86K
Relative Volume:
0.50
Market Cap:
$686.24M
Revenue:
$28.94M
Net Income/Loss:
$-54.29M
P/E Ratio:
-10.16
EPS:
-0.4647
Net Cash Flow:
$-26.02M
1W Performance:
+1.29%
1M Performance:
+8.51%
6M Performance:
+218.92%
1Y Performance:
+176.02%
1-Day Range:
$4.5306
$4.755
1-Week Range:
$4.5301
$4.915
52-Week Range:
$1.30
$5.43
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
4.72 | 686.24M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy - Zacks Investment Research
OmniAb, Inc.Common Stock (Nasdaq:OABI) Detailed Stock Data - The Chronicle-Journal
OmniAb Inc. OABI Stock Holds Support As Traders Weigh Weak Margins - StocksToTrade
OmniAb Inc. Stock Holds Range As Traders Weigh Deep Losses Against Strong Balance Sheet - timothysykes.com
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
OmniAb Company Profile & Introduction - Moomoo
OmniAb Company Profile & Introduction - Moomoo
OABI Looks 50.3% Overvalued on GF Value™ - GuruFocus
Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? - finance.yahoo.com
OmniAb to Participate in Upcoming Investor Conferences - Yahoo Finance
OmniAb (OABI) Earnings Reading: EPS Beats Its Estimate at the Close; Post-Earnings: The Share Price Adds 8.78%EPS Surprise History - vinanet.vn
OmniAb (OABI) Results at a Glance: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Report: The Market Price Moves 0.70% Higher at the CloseEarnings Stability Report - vinanet.vn
OmniAb (OABI) Results at a Glance: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Report: The Market Price Moves 0.70% Higher at the CloseUpward Estimate Revision - dars.gov.et
OmniAb (OABI) Quarter in Focus: The Available Earnings Metric Delivers a Beat; Share Move: The Market Price Moves 1.79% Higher at the CloseBanking Earnings Report - vinanet.vn
OmniAb secures up to $370m Lilly deal for ion channel program - BioXconomy
Truist Financial Maintains OmniAb(OABI.US) With Buy Rating - Moomoo
OmniAb (OABI) Quarter in Focus: The Available Earnings Metric Delivers a Beat; Share Move: The Market Price Moves 1.79% Higher at the ClosePositive Surprise Momentum - siam.in
OmniAb signs $370 million ion channel discovery deal with Eli Lilly - The Pharma Letter
OmniAb boosts 2026 cash guidance after milestone-rich Eli Lilly deal validates its biotech platform. - Pluang
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
Analysts Offer Insights on Healthcare Companies: OmniAb (OABI), Neurocrine (NBIX) and Evaxion Biotech (EVAX) - The Globe and Mail
OmniAb: Lilly-Style Partners Paying Attention To This Early-Stage Biotech (NASDAQ:OABI) - Seeking Alpha
OmniAb Company Profile & Introduction - Moomoo
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook - TradingView
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook - GuruFocus
Eli Lilly Signs $370 Million Ion Channel Deal With OmniAb, Sending Shares Surging - finance.biggo.com
OABI Reiterates by HC Wainwright & Co. -- Price Target Maintained at $11.00 - GuruFocus
Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m - AllSci
Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger - Endpoints News
OmniAb Raises 2026 Financial Guidance - BioSpace
$OmniAb (OABI.US)$ - Moomoo
OmniAb (OABI) Stock Pops As Earnings Beat Resets Growth Outlook - timothysykes.com
Why Is Omniab Stock Rallying After Eli Lilly Deal? - Benzinga
OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat - StocksToTrade
Why is OmniAb stock surging today? By Investing.com - Investing.com South Africa
Why is OmniAb stock surging today? By Investing.com - Investing.com Nigeria
OmniAb Inc. (OABI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
OABI Looks 15.8% Overvalued on GF Value™ - GuruFocus
Why is OmniAb stock surging today? - Investing.com
OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook - StocksToTrade
Why is OmniAb stock surging today? By Investing.com - Investing.com India
Why is OmniAb stock surging today? By Investing.com - Investing.com Canada
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague - Fierce Biotech
Why is OmniAb stock surging today? By Investing.com - Investing.com UK
Why is OmniAb stock surging today? - Investing.com
OmniAb raises 2026 cash guidance to $49-$53 million range - scanx.trade
OmniAb lifts 2026 cash outlook following licensing momentum - Yahoo Finance
OmniAb raises 2026 cash guidance on licensing activity By Investing.com - Investing.com Canada
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omniab Inc Stock (OABI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Option Exercise |
0.00 |
36,459 |
0 |
4,439,736 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Sale |
1.49 |
19,244 |
28,674 |
4,420,492 |
| FOEHR MATTHEW W | Officer |
Apr 07 '26 |
Proposed Sale |
1.49 |
19,244 |
28,577 |
0 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '26 |
Option Exercise |
0.00 |
13,542 |
0 |
268,396 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '26 |
Sale |
1.49 |
6,913 |
10,300 |
261,483 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '26 |
Option Exercise |
0.00 |
13,542 |
0 |
406,242 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '26 |
Sale |
1.49 |
7,157 |
10,664 |
399,085 |
| Berkman Charles S | Officer |
Apr 07 '26 |
Proposed Sale |
1.49 |
7,157 |
10,628 |
0 |
| Berkman Charles S | Chief Legal Officer |
Feb 18 '26 |
Option Exercise |
0.00 |
18,750 |
0 |
402,373 |
| Berkman Charles S | Chief Legal Officer |
Feb 18 '26 |
Sale |
1.71 |
9,673 |
16,541 |
392,700 |
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):